GRGraham L Radford‐Smith

Graham L Radford‐Smith

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Graham L Radford‐Smith has a total of 21 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Will worms really cure Crohn’s disease?

    by G L Radford-Smith


  • Open Access

    CCR5-Δ32 mutation is strongly associated with primary sclerosing cholangitis

    by R Eri, J R Jonsson, N Pandeya, D M Purdie, A D Clouston, N Martin, D Duffy, E E Powell, J Fawcett, T H J Florin, et al.

    CCR5 plays a key role in the distribution of CD45RO+ T cells and contributes to generation of a T helper 1 immune response. CCR5-Δ32 is a 32-bp deletion associated with significant reduction in cell surface expression of the receptor. We investigated the role of CCR5-Δ32 on susceptibility to ulcerative colitis (UC), Crohn's disease (CD) and primary sclerosing cholangitis (PSC). Genotype and allelic association analyses were performed in 162 patients with UC, 131 with CD, 71 with PSC and 419 matched controls. There was a significant difference in CCR5 genotype (OR 2.27, P=0.003) between patients with sclerosing cholangitis and controls. Similarly, CCR5-Δ32 allele frequency was significantly higher in sclerosing cholangitis (17.6%) compared to controls (9.9%, OR 2.47, P=0.007) and inflammatory bowel disease patients without sclerosing cholangitis (11.3%, OR 1.9, P=0.027). There were no significant differences in CCR5 genotype or allele frequency between those with either UC or CD and controls. Genotypes with the CCR5-Δ32 variant were increased in patients with severe liver disease defined by portal hypertension and/or transplantation (45%) compared to those with mild liver disease (21%, OR 3.17, P=0.03). The CCR5-Δ32 mutation may influence disease susceptibility and severity in patients with PSC.


  • Fas ligand and tumour counter‐attack in colorectal cancer stratified according to microsatellite instability status

    by Julie M Michael‐Robinson, Nirmala Pandeya, Margaret C Cummings, Michael D Walsh, Joanne P Young, Barbara A Leggett, David M Purdie, Jeremy R Jass, Graham L Radford‐Smith

    Expression of membrane‐bound Fas ligand (FasL) by colorectal cancer cells may allow the development of an immune‐privileged site by eliminating incoming tumour‐infiltrating lymphocytes (TILs) in a Fas‐mediated counter‐attack. Sporadic colorectal cancer can be subdivided into three groups based on the level of DNA microsatellite instability (MSI). High‐level MSI (MSI‐High) is characterized by the presence of TILs and a favourable prognosis, while microsatellite‐stable (MSS) cancers are TIL‐deficient and low‐level MSI (MSI‐Low) is associated with an intermediate TIL density. The purpose of this study was to establish the relationship between MSI status and FasL expression in primary colorectal adenocarcinoma. Using immunohistochemistry and a selected series of 101 cancers previously classified as 31 MSI‐High, 30 MSI‐Low, and 40 MSS, the present study sought to confirm the hypothesis that increased TIL density in MSI‐High cancers is associated with low or absent membrane‐bound FasL expression, while increased FasL in MSS cancers allows the killing of host TILs. TUNEL/CD3 double staining was also used to determine whether MSS cancers contain higher numbers of apoptotic TILs in vivo than MSI‐High or MSI‐Low cancers. Contrary to the initial hypothesis, it was found that MSI‐High cancers were associated with higher FasL expression (p = 0.04) and a stronger intensity of FasL staining (p = 0.007). In addition, mucinous carcinomas were independently characterized by increased FasL expression (p = 0.03) and staining intensity (p = 0.0005). Higher FasL expression and staining intensity did not correlate with reduced TIL density or increased numbers of apoptotic TILs. However, consistent with the hypothesis that curtailment of the host anti‐tumour immune response contributes to the poor prognosis in MSS cancers, it was found that apoptotic TILs were most abundant in MSS carcinomas and metastatic Dukes' stage C or D tumours (p = 0.004; p = 0.046 respectively). This study therefore suggests that MSS colorectal cancers are killing incoming TILs in an effective tumour counter‐attack, but apparently not via membrane‐bound FasL. Copyright © 2003 John Wiley & Sons, Ltd.


  • Open Access

    Protective role of appendicectomy on onset and severity of ulcerative colitis and Crohn’s disease

    by G L Radford-Smith, J E Edwards, D M Purdie, N Pandeya, M Watson, N G Martin, A Green, B Newman, T H J Florin

    Background and aims: Recent studies on appendicectomy rates in ulcerative colitis and Crohn’s disease have generally not addressed the effect of appendicectomy on disease characteristics. The aims of this study were to compare appendicectomy rates in Australian inflammatory bowel disease patients and matched controls, and to evaluate the effect of prior appendicectomy on disease characteristics. Methods: Patients were ascertained from the Brisbane Inflammatory Bowel Disease database. Controls matched for age and sex were randomly selected from the Australian Twin Registry. Disease characteristics included age at diagnosis, disease site, need for immunosuppression, and intestinal resection. Results: The study confirmed the significant negative association between appendicectomy and ulcerative colitis (odds ratio (OR) 0.23, 95% confidence interval (CI) 0.14–0.38; pConclusions: Compared with patients without prior appendicectomy, appendicectomy before diagnosis delays disease onset in ulcerative colitis and Crohn’s disease and gives rise to a milder disease phenotype in ulcerative colitis.